Skip to main content
. Author manuscript; available in PMC: 2016 Nov 8.
Published in final edited form as: Eur J Gynaecol Oncol. 2013;34(2):113–119.

Table 2.

Chemotherapy regimen.

Bevacizumab
n = 32
Chemotherapy
n = 32
Paclitaxel 19 (59%) 5 (16%)
Cyclophosphamide 9 (28%) 2 (6%)
Doxorubicin 3 (10%) 9 (28%)
Carboplatin/Gemcitabine 1 (3%) 8 (25%)
Pemetrexed 1 (3%)
Carboplatin 1 (3%)
Carboplatin/Paclitaxel 1 (3%)
Etoposide 2 (6%)
Navelbine 1 (3%)
Topotecan 2 (6%)